HA-Pseudotyped Retroviral Vectors for Influenza Antagonist Screening

Influenza infections are initiated by the binding of the influenza hemagglutinin (HA) and the cellular receptor sialic acids. The binding is followed by internalization, endocytosis, and uncoating to release the influenza genome to the cytoplasm. It is conceivable that specific inhibitors that antagonize any one of these events could prevent the replication of influenza infections. The authors made HA pseudotyped retroviral vectors that express luciferase reporter activities upon transduction to several recipient cells. The transduction of the HA-pseudotype virus particles (HApp) was mediated through the specific interactions between an avian HA and the terminal disaccharides of sialic acid (SA) and galactose (Gal) in α-2,3 linkage. The HApp-mediated transduction method was used to develop a high-throughput screening assay and to screen for hits from a fermentation extract library. Specific hits that inhibited the HA-mediated but were noninhibitory to the vesicular stomatitis virus—mediated pseudoviral transductions were identified. A few of these hits have anti-influenza activities that prevent the replication of both H1N1 (WSN) and H5N1 (RG14) influenza viruses. ( Journal of Biomolecular Screening 2009:294-302)

[1]  Chi-Huey Wong,et al.  In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses. , 2008, Antiviral research.

[2]  J. Skehel,et al.  Infectivity Studies of Influenza Virus Hemagglutinin Receptor Binding Site Mutants in Mice , 2008, Journal of Virology.

[3]  Mahbubur Rahman,et al.  Adamantane-Resistant Influenza Infection During the 2004–05 Season , 2008, Emerging infectious diseases.

[4]  A. McGeer,et al.  Antivirals and the control of influenza outbreaks. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  R. Webster,et al.  Neuraminidase Inhibitor-Resistant Recombinant A/Vietnam/1203/04 (H5N1) Influenza Viruses Retain Their Replication Efficiency and Pathogenicity In Vitro and In Vivo , 2007, Journal of Virology.

[6]  D. Pérez,et al.  Genesis of pandemic influenza , 2007, Cytogenetic and Genome Research.

[7]  W. Barclay,et al.  Probing the receptor interactions of an H5 avian influenza virus using a baculovirus expression system and functionalised poly(acrylic acid) ligands. , 2007, Bioorganic & medicinal chemistry.

[8]  R. Weiss,et al.  A sensitive retroviral pseudotype assay for influenza H5N1‐neutralizing antibodies , 2007, Influenza and other respiratory viruses.

[9]  R. Jacobson,et al.  Avian and pandemic influenza: an overview. , 2007, Vaccine.

[10]  I. Barr,et al.  Increased adamantane resistance in influenza A(H3) viruses in Australia and neighbouring countries in 2005. , 2007, Antiviral research.

[11]  Y. Guan,et al.  Tropism of avian influenza A (H5N1) in the upper and lower respiratory tract , 2007, Nature Medicine.

[12]  Erik De Clercq,et al.  Antiviral agents active against influenza A viruses , 2006, Nature Reviews Drug Discovery.

[13]  David J. Stevens,et al.  Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors , 2006, Nature.

[14]  F. Hayden,et al.  Antiviral management of seasonal and pandemic influenza. , 2006, The Journal of infectious diseases.

[15]  E. Turpin,et al.  Inhibition of Influenza Virus Infection by a Novel Antiviral Peptide That Targets Viral Attachment to Cells , 2006, Journal of Virology.

[16]  K. Subbarao,et al.  Performance of Rapid Tests for Detection of Avian Influenza A Virus Types H5N1 and H9N2 , 2006, Journal of Clinical Microbiology.

[17]  James C Paulson,et al.  Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. , 2006, Journal of molecular biology.

[18]  A. Klimov,et al.  Evolution of the receptor binding phenotype of influenza A (H5) viruses. , 2006, Virology.

[19]  Chi-Huey Wong,et al.  Printed covalent glycan array for ligand profiling of diverse glycan binding proteins. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Yi Guan,et al.  Influenza: Emergence and Control , 2004, Journal of Virology.

[21]  D. J. Stevens,et al.  The Structure and Receptor Binding Properties of the 1918 Influenza Hemagglutinin , 2004, Science.

[22]  D. Steinhauer,et al.  Role of hemagglutinin cleavage for the pathogenicity of influenza virus. , 1999, Virology.

[23]  M. Kiso,et al.  Synthesis of sialyl Le(x) ganglioside analogues sulfated at C-6 of either the galactose or N-acetylglucosamine residues, and at both of the galactose and N-acetylglucosamine residues: probes for clarifying the real carbohydrate ligand of L-selectin. , 1996, Carbohydrate research.

[24]  T. Ando,et al.  Synthesis of sialyl Lewis X ganglioside analogues containing modified L-fucose residues. , 1995, Carbohydrate research.

[25]  J. Skehel,et al.  Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. , 2000, Annual review of biochemistry.

[26]  M. Kiso,et al.  Synthesis of sialyl LeX ganglioside analogues modified at C-6 of the galactose residue to elucidate the mechanism of selection recognition. , 1998, Carbohydrate research.